The new vaccine is a combination of GSK’s already-approved vaccines Bexsero and Menveo and is designed to protect against meningitis and blood poisoning caused by the A, B, C, W, and Y ...

In February 2010, a quadrivalent conjugate vaccine (Menveo; Novartis Vaccines and Diagnostics) was approved by the US FDA to prevent invasive meningococcal disease caused by Neisseria meningitidis ...

Penmenvy is a combination of antigens from GSK's established vaccines: Bexsero (Meningococcal Group B vaccine) and Menveo (Meningococcal [Groups A, C, Y, and W-135] Oligosaccharide Diphtheria ...

GSK has garnered FDA approval for its pentavalent meningococcal vaccine Penmenvy ... of GSK's already-approved vaccines Bexsero and Menveo, which together brought in more than £1.4 billion ...

Menveo, a meningococcal vaccine, plays a critical role in controlling the spread of meningitis by offering protection against multiple strains of Neisseria meningitidis, a leading cause of ...

US regulators have approved a new meningitis vaccine developed by GSK ... Penmenvy is a combination of Bexsero and Menveo, which contributed approximately £1.4billion to GSK's turnover last ...